Professor Tapio Visakorpi
Position:
- Professor, Prostate Cancer Research Center, University of Tampere, Institute of Biomedical Technology
Credentials:
- MD, PhD at University of Tampere
Websites:
Biography:
The goal of my group is to profile prostate cancer for genetic and epigenetic alterations using modern molecular genetic tools, including next-generation sequencing. We aim also to generate platforms for personalized treatment. We have also a strong interest towards androgen receptor (AR) gene, amplification of which was first described by our group. One strength in our reasearch is that during the last 20 years we have collected comprehensive biorepository of samples from prostate cancer patients. We utilize those in finding find out the clinical significance of the identified molecular mechanisms and in developing novel biomarkers.
Best publications:
Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinänen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi O-P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genet, 9:401-406, 1995.
Liu W1, Laitinen S1, Khan S, Vihinen M, Kowalski J, Yu G, Chen L, Ewing CM, Eisenberger MA, Carducci MA, Nelson WG, Yegnasubramanian S, Luo J, Wang Y, Xu J, Isaacs WB, Visakorpi T, Bova GS. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nature Med 15:559-565. 2009. 1shared first authors
Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Jänne OA, Visakorpi T. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res 69:8141-8149, 2009.
Urbanucci A, Sahu B, Seppälä J, Larjo A, Latonen LM, Waltering KK, Tammela TLJ, Vessella RL, Lähdesmäki H, Jänne OA, Visakorpi T. Overexpression of androgen receptor enhances the binding of the receptor to the chromatin. Oncogene. 31:2153–2163, 2012.
Jalava SE, Urbanucci A, Latonen L, Waltering KK, Sahu B, Jänne OA, Seppälä J, Lähdesmäki H, Tammela TLJ, Visakorpi T. Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer. Oncogene 31:4460-4471, 2012.
prostate cancer, androgen receptor, genomics, epigenomics, biomarker.
